Bone marrow graft versus peripheral blood graft in haploidentical hematopoietic stem cells transplantation: a retrospective analysis in1344 patients of SFGM-TC registry.

Anti-thymoglobulin Bone marrow Graft source Haploidentical hematopoietic stem cell transplantation Peripheral stem cell

Journal

Journal of hematology & oncology

ISSN: 1756-8722

Titre abrégé: J Hematol Oncol

Pays: England

ID NLM: 101468937

Informations de publication

Date de publication:
07 Jan 2024

Historique:

received: 03 10 2023

accepted: 25 11 2023

medline: 8 1 2024

pubmed: 8 1 2024

entrez: 7 1 2024

Statut: epublish

Résumé

The use of peripheral blood (PB) or bone marrow (BM) stem cells graft in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis remains controversial. Moreover, the value of adding anti-thymoglobulin (ATG) to PTCy is unknown. A total of 1344 adult patients received an unmanipulated haploidentical transplant at 37 centers from 2012 to 2019 for hematologic malignancy. We compared the outcomes of patients according to the type of graft, using a propensity score analysis. In total population, grade II-IV and III-IV acute GVHD (aGVHD) were lower with BM than with PB. Grade III-IV aGVHD was lower with BM than with PB + ATG. All outcomes were similar in PB and PB + ATG groups. Then, in total population, adding ATG does not benefit the procedure. In acute leukemia, myelodysplastic syndrome and myeloproliferative syndrome (AL-MDS-MPS) subgroup receiving non-myeloablative conditioning, risk of relapse was twice greater with BM than with PB (51 vs. 22%, respectively). Conversely, risk of aGVHD was greater with PB (38% for aGVHD II-IV; 16% for aGVHD III-IV) than with BM (28% for aGVHD II-IV; 8% for aGVHD III-IV). In this subgroup with intensified conditioning regimen, risk of relapse became similar with PB and BM but risk of aGVHD III-IV remained higher with PB than with BM graft (HR = 2.0; range [1.17-3.43], p = 0.012).

Identifiants

DOI: 10.1186/s13045-023-01515-4 PMID: 38185663

pubmed: 38185663

doi: 10.1186/s13045-023-01515-4

pii: 10.1186/s13045-023-01515-4

doi:

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

Pagination

Informations de copyright

Références

Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2008;14(6):641–50.

doi: 10.1016/j.bbmt.2008.03.005

Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118(2):282–8.

doi: 10.1182/blood-2011-03-344853 pubmed: 21527516 pmcid: 3138683

Bazarbachi A, Boumendil A, Finel H, Castagna L, Dominietto A, Blaise D, et al. Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma—a LWP-EBMT study. Br J Haematol. 2020;188(5):745–56.

doi: 10.1111/bjh.16182 pubmed: 31498883

Castagna L, Bramanti S, Furst S, Giordano L, Crocchiolo R, Sarina B, et al. Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas. Bone Marrow Transplant. 2014;49(12):1475–80.

doi: 10.1038/bmt.2014.197 pubmed: 25222502

Bashey A, Zhang MJ, McCurdy SR, St. Martin A, Argall T, Anasetti C, et al. Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell–replete haploidentical donor transplantation using post-transplant cyclophosphamide. J Clin Oncol. 2017;35(26):3002–9.

doi: 10.1200/JCO.2017.72.8428 pubmed: 28644773 pmcid: 5590802

Ruggeri A, Labopin M, Bacigalupo A, Gülbas Z, Koc Y, Blaise D, et al. Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide. Cancer. 2018;124(7):1428–37.

doi: 10.1002/cncr.31228 pubmed: 29360162

Mussetti A, De Philippis C, Carniti C, Bastos-Oreiro M, Gayoso J, Cieri N, et al. CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide. Bone Marrow Transplant. 2018;53(12):1522–31.

doi: 10.1038/s41409-018-0183-8 pubmed: 29703966

Bashey A, Zhang X, Jackson K, Brown S, Ridgeway M, Solh M, et al. Comparison of outcomes of hematopoietic cell transplants from T-replete haploidentical donors using post-transplantation cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 allele-matched unrelated donors and HLA-identical sibling donors: a multivariable analysis including disease risk index. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2016;22(1):125–33.

doi: 10.1016/j.bbmt.2015.09.002

O’Donnell PV, Eapen M, Horowitz MM, Logan BR, DiGilio A, Brunstein C, et al. Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis. Bone Marrow Transplant. 2016;51(12):1599–601.

doi: 10.1038/bmt.2016.215 pubmed: 27526284 pmcid: 5143194

Nagler A, Dholaria B, Labopin M, Savani BN, Angelucci E, Koc Y, et al. Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia. Leukemia. 2020;34(10):2766–75.

doi: 10.1038/s41375-020-0850-9 pubmed: 32393841

Duléry R, Brissot E, Mohty M. Combining post-transplant cyclophosphamide with antithymocyte globulin for graft-versus-host disease prophylaxis in hematological malignancies. Blood Rev. 2023. https://doi.org/10.1016/j.blre.2023.101080 .

doi: 10.1016/j.blre.2023.101080 pubmed: 37085459

Arcuri LJ, Hamerschlak N, Rocha V, Bonfim C, Kerbauy MN. Outcomes after haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide: a systematic review and meta-analysis comparing myeloablative with reduced-intensity conditioning regimens and bone marrow with peripheral blood stem cell grafts. Transplant Cell Ther. 2021;27(9):782.e1-782.e7. https://doi.org/10.1016/j.jtct.2021.06.011 .

doi: 10.1016/j.jtct.2021.06.011 pubmed: 34146733